Sacubitril and Vallartan
Entresto is a combination medication containing sacubitril and valsartan, used primarily to treat chronic heart failure in patients with reduced ejection fraction. It works by simultaneously blocking the angiotensin II receptor and inhibiting neprilysin, an enzyme that breaks down beneficial heart peptides, thereby reducing strain on the heart and decreasing cardiovascular death and hospitalization rates.
Entresto is a heart failure medication that combines two blood pressure medications to reduce strain on the heart and prevent cardiovascular death and hospitalizations.
Key facts at a glance
- RxNorm
- 1656341
- Generic
- Entresto
- Class
- brand-name
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Entresto is FDA-approved for treating chronic heart failure in adults with reduced ejection fraction (HFrEF) and for heart failure with preserved ejection fraction (HFpEF) in certain patients. It is also approved for pediatric patients with heart failure due to systemic left ventricular systolic dysfunction.
Entresto combines a neprilysin inhibitor (sacubitril) with an angiotensin II receptor blocker (valsartan). Sacubitril prevents the breakdown of beneficial peptides that promote sodium excretion and vasodilation, while valsartan blocks angiotensin II receptors that cause vasoconstriction and fluid retention. Together, they reduce cardiac strain and improve heart function.
Entresto cannot be used with ACE inhibitors due to angioedema risk; a 36-hour washout period is required when switching. Common side effects include hypotension, hyperkalemia, and kidney impairment. It is contraindicated in pregnancy. Patients should report signs of angioedema (swelling of face, lips, tongue) or hypotension immediately.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy